NCT00183729View on ClinicalTrials.gov

Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Depression
Interventions
DRUG

Memantine

Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.

OTHER

Placebo

Placebo distribution is planned to mimic the active drug.

Trial Locations (1)

15213

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Eric Lenze

OTHER

NCT00183729 - Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults | Biotech Hunter | Biotech Hunter